New nanomedicine is efficient and less aggressive than conventional prostate cancer therapy

New nanomedicine is efficient and less aggressive than conventional prostate cancer therapy

New nanomedicine is efficient and less aggressive than conventional prostate cancer therapy

Prostate cancer is the most common type of cancer among European men; its incidence surpasses 100 cases per 100,000 people.